Brief: Lee's Pharmaceutical Says NDA Of Socazolimab Submitted, Accepted By China's NMPA
27/10/2021 16:22
Oct 27 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* NDA OF SOCAZOLIMAB FOR TREATMENT OF RECURRENT OR
METASTATIC
CERVICAL CANCER SUBMITTED AND ACCEPTED BY CHINA'S NMPA
Source text for Eikon: ID:
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA